Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial

OBJECTIVE: To test the hypothesis that ticagrelor plus aspirin is safe and superior to clopidogrel plus aspirin for reducing high platelet reactivity at 90 days and stroke recurrence in patients with minor stroke or transient ischaemic attack, particularly in carriers of the CYP2C19 loss-of-function...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BMJ
Autori principali: Wang, Yilong, Chen, Weiqi, Lin, Yi, Meng, Xia, Chen, Guohua, Wang, Zhimin, Wu, Jialing, Wang, Dali, Li, Jianhua, Cao, Yibin, Xu, Yuming, Zhang, Guohua, Li, Xiaobo, Pan, Yuesong, Li, Hao, Zhao, Xingquan, Liu, Liping, Lin, Jinxi, Dong, Kehui, Jing, Jing, Johnston, S Claiborne, Wang, David, Wang, Yongjun
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMJ Publishing Group Ltd. 2019
Soggetti:
Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6549283/
https://ncbi.nlm.nih.gov/pubmed/31171523
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmj.l2211
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi